Back to Search
Start Over
E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings
- Source :
- Antiviral Research. 107:31-34
- Publication Year :
- 2014
- Publisher :
- Elsevier BV, 2014.
-
Abstract
- The nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV) has been co-formulated with emtricitabine and tenofovir disoproxil fumarate for initial therapy of HIV-1-infected individuals. RPV, formulated as a long-acting nanosuspension, will also be assessed for its ability to prevent HIV-1 infection in resource limited settings. In this study, we determined whether any pre-existing genetic differences occurred among different HIV-1 subtypes at residues in RT associated with decreased virologic response to RPV. We found that the E138A substitution occurs more frequently in subtype C (range: 5.9–7.5%) than B (range: 0–2.3%) sequences from both treatment-naïve and -experienced individuals (p
- Subjects :
- Tenofovir
Anti-HIV Agents
Mutation, Missense
Human immunodeficiency virus (HIV)
HIV Infections
Biology
medicine.disease_cause
Emtricitabine
Article
chemistry.chemical_compound
Virology
Drug Resistance, Viral
Nitriles
Genotype
medicine
Humans
Pharmacology
Rilpivirine
HIV Reverse Transcriptase
Reverse transcriptase
Pyrimidines
Amino Acid Substitution
chemistry
Virologic response
HIV-1
Limited resources
medicine.drug
Subjects
Details
- ISSN :
- 01663542
- Volume :
- 107
- Database :
- OpenAIRE
- Journal :
- Antiviral Research
- Accession number :
- edsair.doi.dedup.....ac42b2422bb855afe05fa63b28ee1d78